Discontinuation ofPneumocystis cariniiProphylaxis in Patients Infected with Human Immunodeficiency Virus: A Meta‐Analysis and Decision Analysis
Open Access
- 1 December 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (11) , 1901-1909
- https://doi.org/10.1086/323198
Abstract
We performed a meta-analysis and a decision analysis on the discontinuation of prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients infected with human immunodeficiency virus who had adequate immune recovery while receiving highly active antiretroviral therapy. In the meta-analysis (14 studies with 3584 subjects who had discontinued prophylaxis), 8 cases of PCP occurred during 3449 person-years (0.23 cases per 100 person-years [95% confidence interval, 0.10–0.46]). In the decision analysis, mortality and time spent alive without immunodeficiency in the modeled discontinuation strategy were similar to those in the continuation strategy. For patients who received primary prophylaxis, the discontinuation strategy led to slightly fewer episodes of PCP and fewer toxicity-related prophylaxis withdrawals (e.g., 8.6 vs. 34.5 cases per 100 patients during a 10-year period). Patients on the discontinuation strategy were more likely to be receiving trimethoprim-sulfamethoxazole when they became immunodeficient. Comparative results were similar for patients with prior PCP. Discontinuation of PCP prophylaxis in patients with adequate immune recovery is a useful strategy that should be widely considered.Keywords
This publication has 32 references indexed in Scilit:
- Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre studyAIDS, 2001
- Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral TherapyNew England Journal of Medicine, 2001
- Discontinuation of Primary Prophylaxis forPneumocystis cariniiPneumonia and Toxoplasmic Encephalitis in Human Immunodeficiency Virus Type I–Infected Patients: The Changes in Opportunistic Prophylaxis StudyThe Journal of Infectious Diseases, 2000
- Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapyAIDS, 2000
- Discontinuation of Chemoprophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?AIDS, 1999
- Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral TherapyNew England Journal of Medicine, 1999
- Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infectionThe Lancet, 1999
- Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapyThe Lancet, 1999
- Recovery of the Immune System With Antiretroviral TherapyJAMA, 1998